Given the long-term survival of most patients with thyroid cancer, it is very important to
distinguish patients who need aggressive treatment from those who do not. Conventional …

Context: Promoter mutations chr5: 1,295,228 C> T and chr5: 1,295,250 C> T (termed C228T
and C250T, respectively) in the gene for telomerase reverse transcriptase (TERT) have …

Background: TERT encodes the reverse transcriptase component of telomerase, which adds
telomere repeats to chromosome ends, thus enabling cell replication. Telomerase activity is …

Papillary thyroid carcinoma (PTC) is the most common type of endocrine malignancy and
accounts for~ 80% of thyroid carcinomas in adults and 90% in children. Risk stratification is …

TERT promoter mutations are emerging prognostic biomarkers in multiple cancers and are
found in highly aggressive thyroid cancer. Our aim is to investigate the prognostic value of …

TheRomanphilosopherSenecareferstotheid…-called sin or outcome is the result of a series
of complex interconnected factors. This rings true of much of biology, particularly cancer …

The 2013 discovery of Telomerase reverse transcriptase (TERT) promoter mutations chr5,
1,295,228 C> T (C228T) and 1,295,250 C> T (C250T) in thyroid cancer represents an …

The role of telomerase reverse transcriptase (TERT) gene promoter mutations in the
aggressiveness of papillary thyroid cancer (PTC) remains to be further investigated. Here we …

Background: Distant metastases uncommonly occur in differentiated thyroid carcinoma
(DTC), but they are a frequent cause of thyroid cancer–related death. Genomic alterations in …

Background Mutations of BRAF V600E and TERT promoters are associated with thyroid
cancer development. This study further investigated association of these mutations with …